{"classes":[{"categories":[{"measurements":[{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG000","spread":"NA","value":"1.39"},{"groupId":"OG001","spread":"40.1","value":"1.93"},{"groupId":"OG002","spread":"5.47","value":"1.49"},{"groupId":"OG003","spread":"75.5","value":"2.41"},{"groupId":"OG004","spread":"9.91","value":"1.96"},{"groupId":"OG005","spread":"54.5","value":"2.30"},{"groupId":"OG006","spread":"44.5","value":"3.66"},{"groupId":"OG007","spread":"17.9","value":"3.97"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"1.55"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG009","spread":"NA","value":"1.42"},{"groupId":"OG010","spread":"12.8","value":"2.64"},{"groupId":"OG011","spread":"20.8","value":"1.93"},{"groupId":"OG012","spread":"9.30","value":"2.61"},{"groupId":"OG013","spread":"41.8","value":"2.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 1"},{"categories":[{"measurements":[{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG000","spread":"NA","value":"1.41"},{"groupId":"OG002","spread":"11.2","value":"1.36"},{"groupId":"OG003","spread":"22.8","value":"3.22"},{"groupId":"OG004","spread":"13.7","value":"1.95"},{"groupId":"OG005","spread":"43.2","value":"2.49"},{"groupId":"OG006","spread":"42.4","value":"3.78"},{"groupId":"OG007","spread":"70.8","value":"2.79"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG009","spread":"NA","value":"2.33"},{"groupId":"OG010","spread":"16.8","value":"2.16"},{"groupId":"OG011","spread":"20.0","value":"2.10"},{"groupId":"OG012","spread":"13.0","value":"2.55"},{"groupId":"OG013","spread":"18.9","value":"3.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Total Antibody Cycle 1"},{"categories":[{"measurements":[{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG000","spread":"NA","value":"1.75"},{"groupId":"OG001","spread":"25.6","value":"1.89"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG002","spread":"NA","value":"1.88"},{"groupId":"OG003","spread":"118","value":"3.95"},{"groupId":"OG004","spread":"29.0","value":"2.49"},{"groupId":"OG005","spread":"43.5","value":"3.15"},{"groupId":"OG006","spread":"33.4","value":"4.08"},{"groupId":"OG007","spread":"51.7","value":"3.28"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"2.60"},{"groupId":"OG009","spread":"31.9","value":"1.85"},{"groupId":"OG010","spread":"42.4","value":"2.54"},{"groupId":"OG011","spread":"29.7","value":"2.24"},{"groupId":"OG012","spread":"21.4","value":"2.30"},{"groupId":"OG013","spread":"20.0","value":"3.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 2"},{"categories":[{"measurements":[{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG000","spread":"NA","value":"2.22"},{"groupId":"OG001","spread":"27.1","value":"1.99"},{"groupId":"OG002","spread":"17.4","value":"2.10"},{"groupId":"OG003","spread":"66.3","value":"2.86"},{"groupId":"OG004","spread":"29.1","value":"2.67"},{"groupId":"OG005","spread":"79.1","value":"2.58"},{"groupId":"OG006","spread":"48.2","value":"3.92"},{"groupId":"OG007","spread":"27.6","value":"4.70"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"6.09"},{"groupId":"OG009","spread":"18.7","value":"2.37"},{"groupId":"OG010","spread":"47.0","value":"3.13"},{"groupId":"OG011","spread":"22.5","value":"2.24"},{"groupId":"OG012","spread":"20.1","value":"2.97"},{"groupId":"OG013","spread":"35.1","value":"3.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Total Antibody Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"}],"units":"Participants"}],"title":"Unconjugated SG3199 Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"}],"units":"Participants"}],"title":"Unconjugated SG3199 Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"description":"The PK profile included the Thalf of ADCT-301 in serum total antibody and PBD-conjugated antibody. For participants treated with ADCT-301 in combination with pembrolizumab, the collection of PK data was stopped upon consultation with the Sponsor if ADCT-301 administration was discontinued and pembrolizumab continues.\n\nUpon consultation with the Sponsor, no further PK samples were collected, ADCT-301 was permanently discontinued and pembrolizumab continues as single agent.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"ADCT-301 Monotherapy 20 µg/kg"},{"description":"Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"ADCT-301 Monotherapy 30 µg/kg"},{"description":"Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"ADCT-301 Monotherapy 45 µg/kg"},{"description":"Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"ADCT-301 Monotherapy 60 µg/kg"},{"description":"Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"ADCT-301 Monotherapy 80 µg/kg"},{"description":"Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"ADCT-301 Monotherapy 100 µg/kg"},{"description":"Participants received 125 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG006","title":"ADCT-301 Monotherapy 125 µg/kg"},{"description":"Participants received 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG007","title":"ADCT-301 Monotherapy 150 µg/kg"},{"description":"Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG008","title":"ADCT-301 Combination Therapy 20 µg/kg + Pemb"},{"description":"Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG009","title":"ADCT-301 Combination Therapy 30 µg/kg + Pemb"},{"description":"Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG010","title":"ADCT-301 Combination Therapy 45 µg/kg + Pemb"},{"description":"Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG011","title":"ADCT-301 Combination Therapy 60 µg/kg + Pemb"},{"description":"Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG012","title":"ADCT-301 Combination Therapy 80 µg/kg + Pemb"},{"description":"Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG013","title":"ADCT-301 Combination Therapy 100 µg/kg + Pemb"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Analysis Set: The PK analysis set consisted of all participants who received study drug and had at least 1 pre-C1D1 and 1 post-dose valid assessment.\n\nThe overall number of participants analyzed represents the number of participants with available PK data at any timepoint.\n\nIncludes participants with available data at each timepoint.","reportingStatus":"POSTED","timeFrame":"C1D1, from Pre-dose to 4 hr, 96 hr, 168 hr and 336 hr post dose; C2D1, from Pre-dose to 4 hr, 48 hr, 96 hr, 168 hr and 336 hr post dose","title":"Apparent Terminal Elimination Half-life (Thalf) of ADCT-301 in Serum Total Antibody, PBD-conjugated Antibody, and Unconjugated Warhead SG3199","type":"SECONDARY","unitOfMeasure":"days"}